<code id='AA59AB1A5D'></code><style id='AA59AB1A5D'></style>
    • <acronym id='AA59AB1A5D'></acronym>
      <center id='AA59AB1A5D'><center id='AA59AB1A5D'><tfoot id='AA59AB1A5D'></tfoot></center><abbr id='AA59AB1A5D'><dir id='AA59AB1A5D'><tfoot id='AA59AB1A5D'></tfoot><noframes id='AA59AB1A5D'>

    • <optgroup id='AA59AB1A5D'><strike id='AA59AB1A5D'><sup id='AA59AB1A5D'></sup></strike><code id='AA59AB1A5D'></code></optgroup>
        1. <b id='AA59AB1A5D'><label id='AA59AB1A5D'><select id='AA59AB1A5D'><dt id='AA59AB1A5D'><span id='AA59AB1A5D'></span></dt></select></label></b><u id='AA59AB1A5D'></u>
          <i id='AA59AB1A5D'><strike id='AA59AB1A5D'><tt id='AA59AB1A5D'><pre id='AA59AB1A5D'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:6
          Blue Cross Blue Shield website seen on several laptop screens. -- health business coverage from STAT
          Adobe

          A program that undergirds the Affordable Care Act’s health insurance marketplaces continues to bolster the balance sheets of large Blue Cross Blue Shield companies, according to a STAT analysis of new federal data.

          Conversely, that same program — called “risk adjustment” — has created substantial financial burdens for startup insurers including Bright Health Group, which has now exited all health insurance markets, and Friday Health Plans, which has shut down.

          advertisement

          More than two dozen BCBS insurers are projected to collect more than $4.7 billion from competing insurers on the ACA marketplaces, according to the analysis. The biggest amounts are concentrated among a few dominant Blues conglomerates.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Tocagen's brain cancer gene therapy trial continues. Investors worry
          Tocagen's brain cancer gene therapy trial continues. Investors worry

          MichelleMonje/StanfordUniversity/NIHTocagen(TOCA)saidTuesdaythataPhase3clinicaltrialinvolvinganovelg

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          FDA approves first new drug developed for postpartum depression

          AdobeTheFoodandDrugAdministrationonTuesdayapprovedbrexanolone,thefirstdrugspecificallytargetedtotrea